When putting together your watch list, look for stocks with an 80 or higher RS Rating. Rhythm Pharmaceuticals just cleared that benchmark with an upgrade from 71 to 81.
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the top-performing stocks often have an 80 or better RS Rating as they launch their biggest price moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
While it's not currently an ideal time to jump in, see if the stock is able to offer and clear a proper buy point.
Rhythm Pharmaceuticals posted 0% earnings growth last quarter, while sales growth came in at 73%.
Rhythm Pharmaceuticals holds the No. 92 rank among its peers in the Medical-Biomed/Biotech industry group. GeneDx Holdings, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
